title: Can psychedelic compounds play a part in drug dependence therapy?
abstract: After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.
authors.affiliation: Ben Sessa, MBBS, MRCPsych, AddAction, Weston-Super-Mare, Cardiff University Medical School, UK; Matthew W. Johnson, PhD, Johns Hopkins School of Medicine, Baltimore, USA.
authors.forename: Ben
authors.initials: B
authors.lastname: Sessa
authors.affiliation: Ben Sessa, MBBS, MRCPsych, AddAction, Weston-Super-Mare, Cardiff University Medical School, UK; Matthew W. Johnson, PhD, Johns Hopkins School of Medicine, Baltimore, USA.
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Johnson
mesh_terms: D006213:Hallucinogens / Q000627:therapeutic use*; D006801:Humans; D019966:Substance-Related Disorders / Q000188:drug therapy*
chemical_list: D006213:Hallucinogens